Cargando…

IL-10-providing B cells govern pro-inflammatory activity of macrophages and microglia in CNS autoimmunity

B cells contribute to chronic inflammatory conditions as source of antibody-secreting plasma cells and as antigen-presenting cells activating T cells, making anti-CD20-mediated B cell depletion a widely used therapeutic option. B cells or B cell subsets may, however, exert regulatory effects, while...

Descripción completa

Detalles Bibliográficos
Autores principales: Geladaris, Anastasia, Häusser-Kinzel, Silke, Pretzsch, Roxanne, Nissimov, Nitzan, Lehmann-Horn, Klaus, Häusler, Darius, Weber, Martin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020302/
https://www.ncbi.nlm.nih.gov/pubmed/36854993
http://dx.doi.org/10.1007/s00401-023-02552-6
Descripción
Sumario:B cells contribute to chronic inflammatory conditions as source of antibody-secreting plasma cells and as antigen-presenting cells activating T cells, making anti-CD20-mediated B cell depletion a widely used therapeutic option. B cells or B cell subsets may, however, exert regulatory effects, while to date, the immunological and/or clinical impact of these observations remained unclear. We found that in multiple sclerosis (MS) patients, B cells contain regulatory features and that their removal enhanced activity of monocytes. Using a co-culture system, we identified B cell-provided interleukin (IL)-10 as key factor in controlling pro-inflammatory activity of peripheral myeloid cells as well as microglia. Depleting B cells via anti-CD20 in a mouse model of MS unleashed the activity of myeloid cells and microglia and accelerated disease severity; in contrast, adoptive transfer of IL-10-providing B cells restored in vivo control of central nervous system (CNS) macrophages and microglia and reversed clinical exacerbation. These findings suggest that B cells exert meaningful regulatory properties, which should be considered when designing novel B cell-directed agents. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00401-023-02552-6.